Brixton Biosciences Announces $33M Series B to Advance the Field of Pain Management

Gunderson Dettmer represented client Brixton Biosciences, a clinical stage life sciences company commercializing technology out of Massachusetts General Brigham, in its $33 million Series B financing led by Schooner Capital. Brixton Biosciences develops novel therapies to address the crucial unmet needs in the field of pain management, which has historically been dominated by systemic medicine. The new capital will enable the company to immediately pursue two pivotal clinical studies to treat knee pain associated with osteoarthritis as well as knee replacement surgery– and to ultimately expand the applicability of its Neural Ice™ platform beyond the knee to multiple indications in pain with a simple, ultra-long acting injectable drug-free nerve block.

In the announcement of the transaction, Brixton Biosciences Chief Executive Officer Sameer Sabir said, "We are delighted to welcome our new investors, led by Schooner Capital, as well as all of our existing investors, on our journey to bring to market products that disrupt the way we have traditionally come to think of pain treatment. As we use the proceeds of this funding to enter into regulatory clinical studies, our goal is to deliver a simple injectable nerve block that lasts for several months, rather than a day or so."

The Gunderson Dettmer deal team was led by David Gammell and included Alexandra Noymer and Jordana Douglas.

Companies
Brixton Biosciences
Schooner Capital